Joe has advised clients on IP-related issues for a broad range of cutting-edge technologies, including:

• Artificial intelligence/machine learning (e.g., facial recognition, AI- and biomarker-based disease diagnostics and prognostics)
• Autonomous driving
• Augmented reality (AR)
• Image analysis
• Expert systems
• In silico drug design
• On-demand drug production
• 3D additive printing
• Nanomaterials (e.g., graphene)
• Biologicals (e.g., recombinant proteins, fusion proteins, antibodies, antibody-drug conjugates for various disease indications and diagnostics)
• Medical devices (e.g., ultrasound technologies, microfluidics), and other systems such as atomic force microscopy (AFM) and scanning force microscopy (SFM)
• Plasma
• Fluorescence imaging and diagnostic imaging
• Next-generation sequencing (NGS)
• CRISPR gene editing and treatment
• RNAi
• Stem cells
• Vaccines
• Gene therapy
• Drug compositions/drug conjugation and delivery systems
• CAR-T
• CAR-NK
• TCR
• Animal feeds